CARDIOPROTECTION POTENTIAL IN CORONARY HEART DISEASE TREATMENT
Aim. To investigate effectiveness and safety of trimetazidine MB in the complex treatment of stable angina. In total, 90 patients were examined – 57 women and 33 men aged 48-70 years (mean age 61,4 ± 6,03 years). All participants received trimetazidine MB (Deprenorm MB) for 3 months (35 mg twice per...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2009-12-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/1401 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849341509695963136 |
|---|---|
| author | N. A. Shostak O. G. Smolenskaya A. V. Panov A. A. Klimenko D. Yu. Andriyashkina N. A. Tverdova |
| author_facet | N. A. Shostak O. G. Smolenskaya A. V. Panov A. A. Klimenko D. Yu. Andriyashkina N. A. Tverdova |
| author_sort | N. A. Shostak |
| collection | DOAJ |
| description | Aim. To investigate effectiveness and safety of trimetazidine MB in the complex treatment of stable angina. In total, 90 patients were examined – 57 women and 33 men aged 48-70 years (mean age 61,4 ± 6,03 years). All participants received trimetazidine MB (Deprenorm MB) for 3 months (35 mg twice per day). The treatment was associated with reduced angina attack incidence and decreased dose of isosorbide dinitrate, taken during angina attacks. Functional class (FC) of angina was also reduced. Conclusion. Deprenorm MB could be recommended for complex treatment of the patients with coronary heart disease and stable effort angina, who already receive standard anti-anginal therapy. |
| format | Article |
| id | doaj-art-2205ceb66d1f4a50bce2e223b97f9fd2 |
| institution | Kabale University |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| publishDate | 2009-12-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj-art-2205ceb66d1f4a50bce2e223b97f9fd22025-08-20T03:43:37Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202009-12-010625281189CARDIOPROTECTION POTENTIAL IN CORONARY HEART DISEASE TREATMENTN. A. Shostak0O. G. Smolenskaya1A. V. Panov2A. A. Klimenko3D. Yu. Andriyashkina4N. A. Tverdova5Кафедра факультетской терапии им. акад. А.И. Нестерова ГОУ ВПО РГМУ Росздрава, Москвакафедра внутренних болезней №1 с курсом эндокринологии и клинической фармакологии ГОУ ВПР УГМА Росздрава, ЕкатеринбургФГУ ФЦСКиЭ им. В.А. Алмазова Росмедтехнологий, Санкт-ПетербургКафедра факультетской терапии им. акад. А.И. Нестерова ГОУ ВПО РГМУ Росздрава, МоскваКафедра факультетской терапии им. акад. А.И. Нестерова ГОУ ВПО РГМУ Росздрава, МоскваКафедра факультетской терапии им. акад. А.И. Нестерова ГОУ ВПО РГМУ Росздрава, МоскваAim. To investigate effectiveness and safety of trimetazidine MB in the complex treatment of stable angina. In total, 90 patients were examined – 57 women and 33 men aged 48-70 years (mean age 61,4 ± 6,03 years). All participants received trimetazidine MB (Deprenorm MB) for 3 months (35 mg twice per day). The treatment was associated with reduced angina attack incidence and decreased dose of isosorbide dinitrate, taken during angina attacks. Functional class (FC) of angina was also reduced. Conclusion. Deprenorm MB could be recommended for complex treatment of the patients with coronary heart disease and stable effort angina, who already receive standard anti-anginal therapy.https://russjcardiol.elpub.ru/jour/article/view/1401stable anginacytoprotectiontrimetazidine mb |
| spellingShingle | N. A. Shostak O. G. Smolenskaya A. V. Panov A. A. Klimenko D. Yu. Andriyashkina N. A. Tverdova CARDIOPROTECTION POTENTIAL IN CORONARY HEART DISEASE TREATMENT Российский кардиологический журнал stable angina cytoprotection trimetazidine mb |
| title | CARDIOPROTECTION POTENTIAL IN CORONARY HEART DISEASE TREATMENT |
| title_full | CARDIOPROTECTION POTENTIAL IN CORONARY HEART DISEASE TREATMENT |
| title_fullStr | CARDIOPROTECTION POTENTIAL IN CORONARY HEART DISEASE TREATMENT |
| title_full_unstemmed | CARDIOPROTECTION POTENTIAL IN CORONARY HEART DISEASE TREATMENT |
| title_short | CARDIOPROTECTION POTENTIAL IN CORONARY HEART DISEASE TREATMENT |
| title_sort | cardioprotection potential in coronary heart disease treatment |
| topic | stable angina cytoprotection trimetazidine mb |
| url | https://russjcardiol.elpub.ru/jour/article/view/1401 |
| work_keys_str_mv | AT nashostak cardioprotectionpotentialincoronaryheartdiseasetreatment AT ogsmolenskaya cardioprotectionpotentialincoronaryheartdiseasetreatment AT avpanov cardioprotectionpotentialincoronaryheartdiseasetreatment AT aaklimenko cardioprotectionpotentialincoronaryheartdiseasetreatment AT dyuandriyashkina cardioprotectionpotentialincoronaryheartdiseasetreatment AT natverdova cardioprotectionpotentialincoronaryheartdiseasetreatment |